ElizabethR.PlimackMDMS
Oncology • Philadelphia, PAGenitourinary Oncology
Chief, Division of Genitourinary Medical Oncology. Director, Genitourinary Clinical Research. Associate Professor, Department of Hematology/Oncology.
Dr. Plimack is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Fox Chase Cancer Center
Philadelphia, PA 19111Phone+1 215-728-6900Fax+1 215-728-3639
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
NYU Grossman School of MedicineResidency, Internal Medicine, 2002 - 2005- New York University School of MedicineClass of 2002
Certifications & Licensure
PA State Medical License 2008 - 2024
TX State Medical License 2005 - 2008- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- Dose Dense MVAC for Muscle Invasive Bladder Cancer Start of enrollment: 2009 Dec 07
- Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2010 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 146 citationsInhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.Toni K. Choueiri, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan
Nature Medicine. 2021-04-22 - 1454 citationsPan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapyRazvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy
Science. 2018-10-12 - 49 citationsPhase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid TumorsPaul Haluska, Michael E. Menefee, Elizabeth R. Plimack, Jonathan E. Rosenberg, Donald W. Northfelt
Clinical Cancer Research. 2014-09-15
Journal Articles
- Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based ImmunotherapyJonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine
Press Mentions
ASCO GU 2023: Update on Bladder-Sparing Treatment Trial: RETAIN BLADDERFebruary 15th, 2023- Neoadjuvant Chemotherapy Shows “Clear Benefit” in Upper Tract Urothelial CarcinomaJanuary 26th, 2023
- Practice-Changing Presentations in Renal Cell Carcinoma: Insights from ASCO® 2021July 5th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
